GHRP-2

What it is

GHRP-2 is the synthetic growth-hormone-releasing peptide also called pralmorelin. FDA's substance record defines it as a specific sequence with nonstandard amino-acid residues. It is not a generic label for every growth-hormone secretagogue.

The substance name does not establish salt form, formulation, route, concentration, purity, sterility, aggregation state, or equivalence to a study product. GHRP-2 is not GHRP-6/Hexapeptide-2 or Hexarelin/examorelin.

Why people care

Reader interest centers on physique, recovery, sleep, and growth-hormone claims, while the identified controlled human record primarily measures acute appetite and endocrine responses rather than those patient-important outcomes.

What humans actually show

Small human studies show that GHRP-2 can acutely increase growth hormone and food intake, while a five-day study found an attenuating hormone response and no mean IGF-I increase. Those endpoints do not establish muscle, fat-loss, recovery, sleep, performance, or long-term safety benefits, and FDA records compounding-specific quality concerns plus serious-event reports for which causality has not been established.

• other human — Seven lean, healthy adult men in a placebo-controlled crossover experiment; Route: Subcutaneous infusion of defined research material; Outcome: Buffet-meal energy intake and serum growth hormone during an acute experiment: Food intake was higher during GHRP-2 than saline, and serum growth hormone increased. The seam: The abstract does not state random allocation; Very small sample; Acute laboratory meal; No body-composition, strength, healing, recovery, performance, or long-term safety outcome; Does not authenticate another product.
• other human — Nine healthy young men studied across five days; Route: Daily subcutaneous research exposure; Outcome: Growth hormone response, IGF-I, IGF-binding protein-3, and osteocalcin: Growth-hormone responses attenuated between the first and later study days; mean IGF-I did not increase and osteocalcin increased as a biomarker. The seam: Uncontrolled short study; Biomarker outcomes; No muscle, fat, recovery, sleep, or clinical-benefit measurement; Cannot characterize long-term safety.
• other human — Six healthy young adults and six healthy elderly participants; Route: Single intravenous research challenge; Outcome: Growth hormone, prolactin, ACTH, and cortisol responses compared with Hexarelin and other endocrine stimuli: Both age cohorts had acute GH responses; the reported prolactin, ACTH, and cortisol increases with GHRP-2 and Hexarelin were findings in the young cohort. The seam: Small endocrine physiology study; The non-GH findings cannot be transferred to the elderly cohort; No patient-important outcome; GHRP-2 and Hexarelin remain distinct substances; Does not define chronic adverse-effect incidence.

Mechanistic and nonhuman evidence

• cell — Cultured human ovarian granulosa cells; Route: Laboratory cell exposure; Outcome: Inflammatory signaling and mediator expression after a protein-kinase-C stimulus: GHRP-2 altered several inflammatory signaling and mediator measures in the cell model. The seam: Cell evidence; Does not establish treatment of inflammation in people; No product-quality or clinical-safety conclusion.
• mechanistic — Ovine and rat pituitary cells; Route: In-vitro exposure; Outcome: Intracellular signaling and growth-hormone release: GHRP-2 and GHRP-6 showed different signaling patterns in the experimental pituitary-cell systems. The seam: Nonhuman cell systems; Mechanistic distinction is not a clinical benefit; Cannot establish human dose-response or safety.

FDA and U.S. status

FDA currently lists injectable and nasal GHRP-2 in category 2 under the 503B interim policy and identifies potential significant safety risks. An exact active-ingredient Drugs@FDA API search returned no GHRP-2 or pralmorelin match; this draft records that dated database result without converting it into a broader approval, legality, or availability conclusion.

Risks and warning limits

• theoretical: FDA says compounded injectable and nasal GHRP-2 may pose immunogenicity risk because of aggregation and peptide-related impurities and notes added characterization complexity from an unnatural amino acid.
• case report or safety signal: FDA reports awareness of serious adverse events including increased insulin requirement, death in critically ill study subjects, infection, and pancreatitis, while expressly stating that causality has not been established.
• not characterized: No FDA-approved U.S. GHRP-2 prescribing information was identified, so a complete labeled contraindication, warning, pregnancy, adverse-reaction, and interaction profile is not available from an approved product record.

What remains unknown

• Controlled human effects on strength, lean mass, fat loss, injury recovery, sleep quality, performance, and healthy longevity remain unestablished by the identified record.
• Long-term adverse effects, contraindications, pregnancy effects, immunogenicity by route, rare events, and a complete interaction profile remain incompletely characterized.
• The causal role of GHRP-2 in the serious events summarized by FDA remains unresolved in FDA's current wording.

Product identity and quality limits

• A GHRP-2 or pralmorelin name does not establish sequence, form, concentration, purity, sterility, aggregation state, peptide-impurity profile, or stability.
• A defined research material cannot authenticate an unrelated compounded or online product.

What has been studied together

• Hexarelin — coadministration studied: A small human endocrine study compared separate acute challenges with GHRP-2 and Hexarelin; it did not test a fixed combination or establish interchangeability, compatibility, or long-term safety.
• Other endocrine probes or peptides — no direct evidence: The July 27, 2026 exact-substance search did not identify adequate clinical-outcome evidence for consumer-style combinations. Missing evidence does not establish compatibility or safety.

What people are hearing

These are claims this profile checks, not established conclusions.

• Claim under review: “An acute growth-hormone rise proves GHRP-2 builds muscle or speeds recovery.”
• Claim under review: “GHRP-2 is interchangeable with GHRP-6 or Hexarelin.”
• Claim under review: “A product called GHRP-2 has the same identity and safety profile as research material.”

Questions readers raise

• No reproducible community sample was collected for this profile.

The community-signal layer is not efficacy or safety evidence. Its current limits are:

• No reproducible community sample has been collected for this profile.
• Self-reports would be subject to selection and reporting bias.
• The identity of a product described in a self-report could not be verified.
• Concurrent medicines, behaviors, and health conditions could confound an anecdote.
• Reported outcomes could not be independently verified.
• Anecdotes cannot establish efficacy, safety, approval, product identity, or interaction compatibility.

What would change this answer

• An adequately powered controlled trial measuring patient-important body-composition, performance, recovery, sleep, or other claimed outcomes with complete adverse-event reporting would change the evidence assessment.
• An exact FDA action and prescribing information would change the current U.S. status and labeled-warning boundary.
• Product-level analytical and manufacturing evidence would be required to assess another material; a shared name cannot establish identity.

Sources and records

• WADA — 2026 Prohibited List

• FDA GSRS growth-hormone secretagogue substance records — U.S. Food and Drug Administration
• Certain bulk drug substances for use in compounding that may present significant safety risks — U.S. Food and Drug Administration
• United Pharmacy warning letter — U.S. Food and Drug Administration
• Drugs@FDA API exact active-ingredient search for GHRP-2 — U.S. Food and Drug Administration
• ClinicalTrials.gov intervention search for GHRP-2 — ClinicalTrials.gov
• PubMed Title/Abstract search for GHRP-2 or pralmorelin — National Library of Medicine
• Growth hormone releasing peptide-2, like ghrelin, increases food intake in healthy men — PubMed
• A five day treatment with daily GHRP-2 causes response attenuation and does not stimulate IGF-I secretion — PubMed
• Effects of GHRP-2 and Hexarelin on GH, prolactin, ACTH and cortisol levels in man — PubMed
• GHRP-2 attenuation of inflammation signaling in human ovarian granulosa cells — PubMed
• Effects of GHRP-6 and GHRP-2 on signaling and GH secretion in ovine and rat somatotrophs — PubMed